Synairgen has announce that recruitment of 100 hospitalised patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed.
Synairgen’s clinical trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. The 220 patient trial comprises 100 patients initiated in hospital and 120 patients initiated in the home setting. The patients participating in the hospital setting have been recruited across a number of NHS trusts and the trial has been adopted by the NIHR Respiratory Translational Research Collaboration which is comprised of leading centers in respiratory medicine in the UK whose internationally recognized experts are working together to accelerate development and discovery for COVID-19. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Results from the hospital setting are expected in July 2020, as announced in the Company’s Preliminary Results statement on 26 May 2020.
“We are pleased to have now completed recruitment in this important study, with initial trial data expected in July 2020. A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic,” Richard Marsden, CEO of Synairgen, said.